ClinicalTrials.gg
WithdrawnNCT01073111ASSESSUpdated Aug 3, 2018

Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents

An interventional study of zotarolimus-eluting stent (ENDEAVOR®) and sirolimus-eluting stents (CYPHER SELECT® PLUS) in Coronary Artery Disease and Atherosclerosis, sponsored by Hyogo Medical University. Withdrawn at 1 site in Japan. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-03.

Sponsored by Hyogo Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
25 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.

Enrollment
100th of 100
0 · median 445
Started
2010
with 18 others
No phase
39 of 134
5 open now
Registered
26th of 134
by date

Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 100th largest by enrollment of the 100 interventional ones that give a count, is one of 19 that started in 2010, is one of 39 with no phase, and was the 26th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 25 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Coronary Artery Disease with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker level.

03

Conditions studied

  • Coronary Artery Disease
  • Atherosclerosis
04

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Significant coronary de novo lesion (> 70% by quantitative angiographic analysis)
  • Patients with stable or acute coronary syndrome considered for coronary revascularization
  • Reference vessel diameter of 2.5 to 3.5 mm by operator assessment

Exclusion criteria

Exclusion Criteria:

  • to anti- agents
  • Ostial lesion within 5 mm from ostium
  • Different DES in other vessel simultaneously
  • Creatinine level 2.5 mg/dL
  • Left main stenosis more than 50%.
  • vein graft lesion
  • Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries
  • 1 year
  • Reference vessel \< 2.5 mm or > 4.0 mm diameter by visual
  • Long lesion that require more than three stents
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    zotarolimus-eluting stents (ENDEAVOR®)

    Device: zotarolimus-eluting stent (ENDEAVOR®)

  • Active comparator
    sirolimus-eluting stents (CYPHER SELECT® PLUS)

    Device: sirolimus-eluting stents (CYPHER SELECT® PLUS)

  • Active comparator
    everolimus-eluting stents (PROMUS®)

    Device: everolimus-eluting stents (PROMUS®)

Interventions

  • Devicezotarolimus-eluting stent (ENDEAVOR®)

    zotarolimus-eluting stent

  • Devicesirolimus-eluting stents (CYPHER SELECT® PLUS)

    sirolimus-eluting stents

  • Deviceeverolimus-eluting stents (PROMUS®)

    everolimus-eluting stents

06

What researchers measure

Primary outcomes

  1. To compare coronary endothelial function after primary angioplasty.

    Time frame: 6 months and 12 months

  2. To compare the presence of neointimal stent strut coverage via optical coherence tomography.

    Time frame: 6 months and 12 months

  3. To compare the serum biomarker levels measured in coronary artery blood.

    Time frame: 6 months and 12 months

07

Study locations

1 site
  • Hyogo College of Medicine
    Nishinomiya, 6638501, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Oct 2011 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2010
First posted
Feb 23, 2010
Start
Apr 2010
Primary completionActual
Oct 2011
CompletionActual
Feb 2017
Last update
Aug 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01073111
Lead sponsor
Hyogo Medical University
Responsible party
Kenichi Fujii (Assistant Professor, Hyogo Medical University) — Principal investigator
First posted
Feb 23, 2010
Start date
Apr 2010
Primary completion
Oct 2011
Completion
Feb 2017
Last update
Aug 3, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion